FDA OKs Teva’s Injectable Treanda

New Drug Approvals

FDA OKs Teva’s Injectable Treanda

FDA Approves Teva’s Injectable Treanda


Sept. 17, 2013 (GLOBES)–Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced that the US Food and Drug Administration (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and chronic lymphocytic leukemia. read all at


Bendamustine (INN, trade names TreakisymRibomustinLevact and Treanda; also known as SDX-105) is a nitrogen mustard used in the treatment of chronic lymphocytic leukemia[1] and lymphomas. It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma.[2]


Bendamustine was first synthesized in 1963 by Ozegowski and Krebs in East Germany(the former German Democratic Republic). Until 1990 it…

View original post 2,964 more words


About luciavazine

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s